Skip to main content
Equibles
ENDV logo

ENDV · Endonovo Therapeutics, Inc. · Metrics

Track ENDV — free

Use ENDV with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ENDV.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.00 At close · Nov 9
Rebalance outlook locked
Going-concern doubt — flagged Dec 29, 2023

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt as to its ability to continue as going concern within one year from issuance date of these unaudited consolidated financial statements.”
View the 10-Q filed Dec 29, 2023
Market Cap
$31,875
Shares
318.75M
Volume · Nov 9 500K Avg daily vol (3M) 753.37K

ENDV metrics

51 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.00
Market cap
$31,875

Price action

23 metrics
Price change (1W)
+0.0%
Price change (30D)
+0.0%
Price change (3M)
+0.0%
Price change (6M)
+0.0%
Price change (YTD)
+0.0%
Price change (1Y)
+0.0%
Trailing year
Price change (5Y)
-99.5%
52-week high
$0.00
52-week low
$0.00
Change from 52-week high
+0.0%
Change from 52-week low
+0.0%
Annualized volatility
0.0%
Annualized volatility (3M)
—
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
—
RSI (14D)
—
Price vs SMA 50
+0.0%
Price vs SMA 200
-23.1%
Avg volume (3M)
753,371
Relative volume
0.7
Average dollar volume
$75

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
318.75M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
27.8×
reciprocal yield 3.6%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.1×
reciprocal yield 802.3%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-13,816.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
139.8×
reciprocal yield 0.7%
EV / revenue historical average (5Y)
106.8×
reciprocal yield 0.9%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
96.2%
Operating margin
-1,023.2%
Trailing 12 months
Net margin
-1,722.2%
Gross profit (TTM)
$246,034
Operating profit (TTM)
−$2.62M
Net income (TTM)
−$4.40M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.00
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.07

Growth

11 metrics
Revenue growth YoY
-86.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$255,723
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+779.4%
Year over year · more shares
Revenue CAGR (3Y)
-24.1%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-539.9%
Debt / equity
—
Current ratio
0.0
EBITDA (TTM)
−$1.97M
Free cash flow (TTM)
—
Quick ratio
0.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$7.09M
Latest balance sheet
Cash & equivalents
$0
Total assets
$815,764
Total debt
$7.09M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$629,904
Capital expenditures (TTM)
—
R&D (TTM)
$0
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1528172 Visit website